期刊
GENES
卷 12, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/genes12050723
关键词
breast cancer; CRISPR; Cas9; tumorigenesis; metastasis
资金
- Terry Fox Foundation's International Run Program [I1032]
Breast cancer is a prevalent and heterogeneous disease with complex pathogenesis, often treated by alleviating symptoms rather than targeting mutations. CRISPR/Cas9 is a groundbreaking gene-editing tool that offers a promising new approach for the treatment of breast cancer, surpassing previous methods in terms of simplicity, efficiency, and affordability.
Breast cancer is one of the most prevalent forms of cancer globally and is among the leading causes of death in women. Its heterogenic nature is a result of the involvement of numerous aberrant genes that contribute to the multi-step pathway of tumorigenesis. Despite the fact that several disease-causing mutations have been identified, therapy is often aimed at alleviating symptoms rather than rectifying the mutation in the DNA sequence. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 is a groundbreaking tool that is being utilized for the identification and validation of genomic targets bearing tumorigenic potential. CRISPR/Cas9 supersedes its gene-editing predecessors through its unparalleled simplicity, efficiency and affordability. In this review, we provide an overview of the CRISPR/Cas9 mechanism and discuss genes that were edited using this system for the treatment of breast cancer. In addition, we shed light on the delivery methods-both viral and non-viral-that may be used to deliver the system and the barriers associated with each. Overall, the present review provides new insights into the potential therapeutic applications of CRISPR/Cas9 for the advancement of breast cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据